Vitespen Completed Phase 2 Trials for Brain and Central Nervous System Tumors Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00905060HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM